Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus in Recurrent Uterine Carcinosarcoma
NCT01061606Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in uterine carcinosarcoma (UCS), sponsored by National Cancer Institute. Primary endpoints: Tumor Response Rate (CR or PR) up to 3 years and Progression Free Survival at 6 months. Started Jan 2010; status: terminated.
02
Drugs
temsirolimus
03
Conditions
uterine carcinosarcoma (UCS)
Beyond the preview
Go deeper on NCT01061606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01061606.